Peringatan Keamanan

Diflucortolone can cause skin irritation, vesicles or red patches on the skin.L1083

Difluocortolone

DB09095

small molecule approved investigational withdrawn

Deskripsi

Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.L1082

Struktur Molekul 2D

Berat 394.459
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of diflucortolone is approximately in the range of 4 to 5 h while the half-life of 3H-diflucortolone valerate is approximately 9 h.[A31459]
Volume Distribusi Less of 1% of the administered dose reaches systemic circulation.[L1086] In order to exert its functions, diflucortolone has to distribute into the living epidermis and upper dermis. Reports have shown that the skin absorption of diflucortolone is rapid where the absorption gets significantly increased in damaged skin. Diflucortolone gets percutaneously absorbed and distributed into organs and tissues where it will be metabolized. When diflucortolone in an ointment form is applied in healthy skin 0.7% of the administered dose is percutaneously absorbed after a 7-hour exposure.[L1085]
Klirens (Clearance) Diflucortolone gets rapidly eliminated and the metabolites produced are the latest in getting eliminated from the body.[L1085]

Absorpsi

The absorption of diflucortolone is made mainly percutaneously but it may be absorbed systemically. The absorption and bioavailability of diflucortolone will be related to the type of formulation found in the medication.A31458 The percutaneous absorption depends on the vehicle, dose, treatment area, duration of treatment, the condition of treatment, the status of penetration barrier and localization of treated area in the body.L1085 Thus, rectal administration of diflucortolone produces a slow and low absorption with an AUC, Cmax and Tmax of 10.8 ng h/ml, 0.75 ng/ml and 4.7 h, respectively.L1084

Metabolisme

The metabolism of diflucortolone is done in the liver where it is very rapidly degraded. After 5 minutes of administration of diflucortolone in a dose of 1mg, there is a concentration of intact diflucortolone in plasma of 6-8 ng/ml. The analysis of the metabolites showed the presence of 11-keto-diflucortolone as the major metabolite in the plasma.A31459

Rute Eliminasi

The elimination of diflucortolone is rapid and complete. After 24 hours of dose administration 56% of the dose was eliminated by the urine and after 7 days 98% of the administered dose was recovered. The excretion of diflucortolone is subdivided in urine which accounts for 75% of the administered dose and in feces that accounts for the other 25% of the administered dose. From the eliminated dose, 30% was formed by unconjugated steroids, 20% as steroid-glucuronides and 10% as steroid-sulfates.A31459

Interaksi Obat

1603 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Difluocortolone.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Difluocortolone.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Difluocortolone.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Difluocortolone.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Difluocortolone.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Difluocortolone.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Difluocortolone.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Difluocortolone.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Difluocortolone.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Difluocortolone.
Pegaspargase The serum concentration of Difluocortolone can be increased when it is combined with Pegaspargase.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Difluocortolone.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Difluocortolone.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Difluocortolone.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Difluocortolone.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Difluocortolone.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Difluocortolone.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Difluocortolone.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Difluocortolone.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Difluocortolone.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Difluocortolone.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Difluocortolone.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Difluocortolone.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Difluocortolone.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Difluocortolone.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Difluocortolone.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Difluocortolone.
Cladribine Difluocortolone may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Difluocortolone.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Difluocortolone.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Difluocortolone.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Difluocortolone.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Difluocortolone.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Difluocortolone.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Difluocortolone.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Difluocortolone.
Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Difluocortolone.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Difluocortolone.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Difluocortolone.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Difluocortolone.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Difluocortolone.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Difluocortolone.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Difluocortolone.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Difluocortolone.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Difluocortolone.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Difluocortolone.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Difluocortolone.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Difluocortolone.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Difluocortolone.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Difluocortolone.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Difluocortolone.
Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Difluocortolone.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Difluocortolone.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Difluocortolone.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Difluocortolone.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Difluocortolone.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Difluocortolone.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Difluocortolone.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Difluocortolone.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Difluocortolone.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Difluocortolone.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Difluocortolone.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Difluocortolone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Difluocortolone.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone.
Tretinoin The metabolism of Tretinoin can be increased when combined with Difluocortolone.
Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Difluocortolone.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Difluocortolone.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Difluocortolone.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Difluocortolone.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Difluocortolone.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Difluocortolone.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Difluocortolone.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Difluocortolone.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Difluocortolone.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Difluocortolone.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Difluocortolone.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Difluocortolone.
Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Difluocortolone.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Difluocortolone.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Difluocortolone.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Difluocortolone.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Difluocortolone.
Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Difluocortolone.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Difluocortolone.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Difluocortolone.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Difluocortolone.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Difluocortolone.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Difluocortolone.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Difluocortolone.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Difluocortolone.
Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Difluocortolone.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Difluocortolone.
Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Difluocortolone.
Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Difluocortolone.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Difluocortolone.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Difluocortolone.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Difluocortolone.

Target Protein

Annexin A3 ANXA3
Glucocorticoid receptor NR3C1

Referensi & Sumber

Artikel (PubMed)

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Nerisalic Oily Cream
    Cream • - • Topical • Canada • Approved
  • Nerisone Cream
    Cream • 0.1 % • Topical • Canada • Approved
  • Nerisone Oily Cream
    Cream • 0.1 % • Topical • Canada • Approved
  • Nerisone Ointment
    Ointment • 0.1 % • Topical • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul